JAZZ - CIK 0001232524
Jazz Pharmaceuticals plc (JAZZ) reported net income of -$356.15M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$356.15M | -163.6% |
| FY 2024 | $560.12M | +35.0% |
| FY 2023 | $414.83M | +285.1% |
| FY 2022 | -$224.06M | +32.0% |
| FY 2021 | -$329.67M | -238.2% |
| FY 2020 | $238.62M | -54.4% |
| FY 2019 | $523.37M | +17.1% |
| FY 2018 | $447.10M | -8.4% |
| FY 2017 |
Jazz Pharmaceuticals plc (JAZZ) reported net income of -$356.15M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Jazz Pharmaceuticals plc's net income declined from $124.98M to -$356.15M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $487.85M |
| +22.9% |
| FY 2016 | $396.83M | +20.4% |
| FY 2015 | $329.54M | +464.4% |
| FY 2014 | $58.39M | -73.0% |
| FY 2013 | $216.31M | -25.0% |
| FY 2012 | $288.59M | +130.9% |
| FY 2011 | $124.98M | - |